Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Gilteritinib for Acute Myeloid Leukemia
Recruiting2 awardsPhase 3
New Haven, Connecticut
This trial is testing a new cancer drug, ASP2215, to see if it can help people with a certain type of leukemia who have not responded to other treatments. The trial will compare how well the new drug works to standard chemotherapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service